| Patents for C12P 21 - Preparation of peptides or proteins (112,499) |
|---|
| 04/21/2005 | WO2005035749A2 Animal product free media and processes for obtaining a botulinum toxin |
| 04/21/2005 | WO2005035748A1 Method for large-scale production of a polypeptide in eukaryote cells and a culture vessel suitable therefor |
| 04/21/2005 | WO2005035741A1 Genomically modified cell |
| 04/21/2005 | WO2005035740A1 Genomically modified cell neutralized to serum-free system |
| 04/21/2005 | WO2005035586A1 Fused protein composition |
| 04/21/2005 | WO2005035583A1 Antibody composition specifically binding to il-5 receptor |
| 04/21/2005 | WO2005035582A1 Composition of antibody capable of specifically binding ccr4 |
| 04/21/2005 | WO2005035581A1 COMPOSITION OF ANTIBODY CAPABLE OF SPECIFICALLY BINDING HUMAN VEGF RECEPTOR Flt-1 |
| 04/21/2005 | WO2005035578A1 Antibody composition specifically binding to ganglioside gm2 |
| 04/21/2005 | WO2005035577A1 Antibody composition specifically binding to ganglioside gd3 |
| 04/21/2005 | WO2005035571A1 Novel glycoprotein and medicinal composition containing the same |
| 04/21/2005 | WO2005035565A1 Il-21 derivatives |
| 04/21/2005 | WO2005035563A1 Process for producing antithrombin iii composition |
| 04/21/2005 | WO2005035553A2 Conjugation of peptides |
| 04/21/2005 | WO2005034988A1 Long-acting molecules in sustained release formulations |
| 04/21/2005 | WO2005034876A2 Use of cell lines to produce active therapeutic proteins |
| 04/21/2005 | WO2005034853A2 Uses of interferons with altered spatial structure |
| 04/21/2005 | WO2005034841A2 Anthrax vaccine |
| 04/21/2005 | WO2005003296A3 Albumin fusion proteins |
| 04/21/2005 | WO2004098490A3 Mesoderm and definitive endoderm cell populations |
| 04/21/2005 | WO2004094608A3 Human procolipase like nucleic acids and polypeptides and their methods of use threof |
| 04/21/2005 | WO2004031400A3 Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
| 04/21/2005 | WO2004009768A3 Viral vectors containing recombination sites |
| 04/21/2005 | WO2002092842A3 Nucleic acids and corresponsing proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer |
| 04/21/2005 | WO2002092841A3 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| 04/21/2005 | US20050085628 Centromere specific monoclonal antibody for use in detection or identification of chromosomal aberrations, and in elucidation of the structure or the mechanism of centromere |
| 04/21/2005 | US20050085627 Nucleotide sequences coding histone methyltransferase for use in identifying modulators for treatment and prevention of asthma disorders |
| 04/21/2005 | US20050085412 Hydrosilation of follicle stimulating hormone; efficiency |
| 04/21/2005 | US20050084969 Method for producing a recombinant polypeptide |
| 04/21/2005 | US20050084936 Human regulatory proteins |
| 04/21/2005 | US20050084933 Product quality enhancement in mammalian cell culture processes for protein production |
| 04/21/2005 | US20050084927 Modified by immobilizing with disulfide-containing compound; mass spectrometry; solid phase synthesis |
| 04/21/2005 | US20050084926 Method for cell-free protein complete post-translational modification |
| 04/21/2005 | US20050084897 DNA encoding human vanilloid receptor VR3 |
| 04/21/2005 | US20050084859 Herbicide metabolizing proteins; ferredoxins; methylation, dehydrogenation; kits |
| 04/21/2005 | US20050084845 Immunoglobulin specific to hepatitis c viral envelope protein for use as tool prevention and treatment of viral diseases |
| 04/21/2005 | US20050084843 System and method for identifying proteins involved in force-initiated signal transduction |
| 04/21/2005 | US20050084503 Continuous cell line for the production of vaccines |
| 04/21/2005 | US20050084496 Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins |
| 04/21/2005 | US20050084491 Use as an immunogen to generate anti-integrin antibodies; a mimotope; vaccinating against angiogenic and metastatic diseases |
| 04/21/2005 | CA2548787A1 Antibody composition specifically binding to ganglioside gm2 |
| 04/21/2005 | CA2542179A1 Il-21 derivatives |
| 04/21/2005 | CA2542130A1 Cell genomically modified to produce polypeptides with an altered glycosylation pattern |
| 04/21/2005 | CA2542125A1 Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
| 04/21/2005 | CA2542121A1 Genomically modified cell neutralized to serum-free system |
| 04/21/2005 | CA2542046A1 Fused protein composition |
| 04/21/2005 | CA2542042A1 Antibody composition specifically binding to il-5 receptor |
| 04/21/2005 | CA2542037A1 Composition of antibody capable of specifically binding ccr4 |
| 04/21/2005 | CA2542035A1 Process for producing antithrombin iii composition |
| 04/21/2005 | CA2541380A1 Use of cell lines to produce active therapeutic proteins |
| 04/21/2005 | CA2540072A1 Animal product free media and processes for obtaining a botulinum toxin |
| 04/21/2005 | CA2539681A1 Nucleic acid molecules encoding novel human low-voltage activated calcium channel proteins, designated - alpha 1i-1 and alpha 1i-2, encoded proteins and methods of use thereof |
| 04/21/2005 | CA2535982A1 Uses of interferons with altered spatial structure |
| 04/20/2005 | EP1524316A2 Method of determining propensity of bacteria for dissolved oxygen instability |
| 04/20/2005 | EP1523679A2 Methods for producing secreted polypeptides having l-asparaginase activity |
| 04/20/2005 | EP1523582A2 Rapid, efiicient purification of hsv-specific t-lymphocytes and hsv antigens identified via same |
| 04/20/2005 | EP1523574A2 Modular recombinatorial display libraries |
| 04/20/2005 | EP1523567A1 Methods of enhancing yields of soluble proteins |
| 04/20/2005 | EP1523558A1 Production of peptides and proteins by accumulation in plant endoplasmic reticulum-derived protein bodies |
| 04/20/2005 | EP1523498A1 Polynucleotides and polypeptides coded by said polynucleotides involved in the synthesis of diketopiperazine derivatives |
| 04/20/2005 | EP1523496A2 Recombinant production of mixtures of antibodies |
| 04/20/2005 | EP1523322A2 Novel proteins and nucleic acids encoding same |
| 04/20/2005 | EP1453977A4 Molecular characteristics of non-small cell lung cancer |
| 04/20/2005 | EP1175435B1 Cephaibols, novel antiparasitics from acremonium tubakii, method for the production and the utilization thereof |
| 04/20/2005 | EP1141326B1 Human akt-3 |
| 04/20/2005 | EP1113817B1 Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies |
| 04/20/2005 | EP1068226B1 Lipopeptides inducing t lymphocytic cytotoxicity bearing at least one auxiliary t epitope, and uses for vaccination |
| 04/20/2005 | EP1009753B1 Hypoxia-regulated genes |
| 04/20/2005 | EP0942994B1 H mutant alpha-amylase enzymes |
| 04/20/2005 | EP0835301B1 Monoclonal antibody directed against rat beta 2 integrin alpha d subunit and corresponding hybridoma |
| 04/20/2005 | EP0813604B1 Control of gene expression in plants by receptor mediated transactivation in the presence of a chemical ligand |
| 04/20/2005 | EP0805859B1 A chemokine receptor able to bind to mcp-1, mip-1 alpha and/or rantes. its uses |
| 04/20/2005 | EP0700430B1 Methods for selectively stimulating proliferation of t cells |
| 04/20/2005 | CN1608078A Gonadotrophins for folliculogenesis |
| 04/20/2005 | CN1607960A Glycoprotein compositions |
| 04/20/2005 | CN1607959A Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells |
| 04/20/2005 | CN1607245A High efficiency fermentation method for pristinamycin |
| 04/20/2005 | CN1607006A Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| 04/20/2005 | CN1607005A Soluble lymphotoxin- beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| 04/20/2005 | CN1197978C In vitro activity assay for human hepatitis B virus (HBV) DNA polymerase, and its use for screening inhibitors of HBV DNA polymerase |
| 04/20/2005 | CN1197968C Disulfide cross-linked glycoprotein hormone analogs, their preparation and use |
| 04/20/2005 | CN1197966C Modulators of TNF receptor associated factor (TRAF), their preparation and use |
| 04/20/2005 | CN1197956C Lactobacillus helvetius producing antihypertensive di- and tripeptides |
| 04/20/2005 | CN1197877C AsLc-IFN fusion protein and its preparation |
| 04/20/2005 | CN1197876C Chimeric protein containing an intramolecular chaperone-like sequence and its application to insulin production |
| 04/20/2005 | CN1197618C Mutant cholera holotoxin as an adjuvant |
| 04/20/2005 | CN1197482C Glyptal composition, its preparation and use |
| 04/19/2005 | US6881832 Comprises nucleotide sequences coding signal sequences for transport of heterologous proteins into preferential cellular compartments |
| 04/19/2005 | US6881823 Comprises nucleotide sequences coding secreted polypeptides for diagnosing, preventing |
| 04/19/2005 | US6881821 Hepatitis-C virus type 4, 5, and 6 |
| 04/19/2005 | US6881747 Small molecules for inhibition of function and drug delivery to leukocytes |
| 04/19/2005 | US6881557 Selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for corresponding CDRs from a library of human germline antibody sequences |
| 04/19/2005 | US6881552 Human protease associated proteins |
| 04/19/2005 | US6881412 Safe and effective live vaccines against Flavobacterium columnare of fish were created through the induction of rifampicin resistance in a native Flavobacterium columnare isolate; these including rifampicin-resistant mutants NRRL |
| 04/19/2005 | US6881404 Enzymatic protein for treating inflammation, thrombosis andrestenosis |
| 04/19/2005 | US6881401 Methods of treatment of immune system related disorders using Neutrokine-alpha |
| 04/19/2005 | US6881395 Ligand for use as tool in the treatment of tumors in humans |
| 04/19/2005 | CA2059137C Enhancement of musculature in animals |
| 04/14/2005 | WO2005033325A1 Method of producing a recombinant polypeptide free of o-linked mannose residues |
| 04/14/2005 | WO2005033303A1 Mammalian cell lines modified for the production of recombinant glycoproteins |